BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31943533)

  • 1. Effect of single-nucleotide polymorphism in TERT promoter on follicular thyroid tumor development.
    Hirokawa T; Arimasu Y; Nakazato Y; Chiba T; Fujiwara M; Kamma H
    Pathol Int; 2020 Apr; 70(4):210-216. PubMed ID: 31943533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
    Wang N; Liu T; Sofiadis A; Juhlin CC; Zedenius J; Höög A; Larsson C; Xu D
    Cancer; 2014 Oct; 120(19):2965-79. PubMed ID: 24898513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological significance of the single nucleotide polymorphism, rs2853669 within the TERT promoter in papillary thyroid carcinoma.
    Hirokawa T; Arimasu Y; Chiba T; Fujiwara M; Kamma H
    Pathol Int; 2020 Apr; 70(4):217-223. PubMed ID: 31943527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory Single Nucleotide Polymorphism Increases TERT Promoter Activity in Thyroid Carcinoma Cells.
    Hirokawa T; Arimasu Y; Chiba T; Nakazato Y; Fujiwara M; Kamma H
    Pathobiology; 2020; 87(6):338-344. PubMed ID: 33227798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TERT Promoter Mutation Spatial Heterogeneity in a Metastatic Follicular Thyroid Carcinoma: Implications for Clinical Work-Up.
    Stenman A; Hysek M; Jatta K; Bränström R; Darai-Ramqvist E; Paulsson JO; Wang N; Larsson C; Zedenius J; Juhlin CC
    Endocr Pathol; 2019 Sep; 30(3):246-248. PubMed ID: 31154561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.
    Liu T; Wang N; Cao J; Sofiadis A; Dinets A; Zedenius J; Larsson C; Xu D
    Oncogene; 2014 Oct; 33(42):4978-84. PubMed ID: 24141777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational burdens and evolutionary ages of thyroid follicular adenoma are comparable to those of follicular carcinoma.
    Jung SH; Kim MS; Jung CK; Park HC; Kim SY; Liu J; Bae JS; Lee SH; Kim TM; Lee SH; Chung YJ
    Oncotarget; 2016 Oct; 7(43):69638-69648. PubMed ID: 27626165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population.
    Qasem E; Murugan AK; Al-Hindi H; Xing M; Almohanna M; Alswailem M; Alzahrani AS
    Endocr Relat Cancer; 2015 Dec; 22(6):901-8. PubMed ID: 26354077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of GPER1, EGFR and CXCR1 in differentiating between malignant follicular thyroid carcinoma and benign follicular thyroid adenoma.
    Zhao L; Zhu XY; Jiang R; Xu M; Wang N; Chen GG; Liu ZM
    Int J Clin Exp Pathol; 2015; 8(9):11236-47. PubMed ID: 26617848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation profiles of follicular thyroid tumors by targeted sequencing.
    Duan H; Liu X; Ren X; Zhang H; Wu H; Liang Z
    Diagn Pathol; 2019 May; 14(1):39. PubMed ID: 31077238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in Mutational Profile between Follicular Thyroid Carcinoma and Follicular Thyroid Adenoma Identified Using Next Generation Sequencing.
    Borowczyk M; Szczepanek-Parulska E; Dębicki S; Budny B; Verburg FA; Filipowicz D; Więckowska B; Janicka-Jedyńska M; Gil L; Ziemnicka K; Ruchała M
    Int J Mol Sci; 2019 Jun; 20(13):. PubMed ID: 31248021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly prevalent TERT promoter mutations in aggressive thyroid cancers.
    Liu X; Bishop J; Shan Y; Pai S; Liu D; Murugan AK; Sun H; El-Naggar AK; Xing M
    Endocr Relat Cancer; 2013 Aug; 20(4):603-10. PubMed ID: 23766237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological differential diagnosis of follicular thyroid tumor and Hürthle cell tumor on the basis of telomere length and hTERT expression.
    Sugishita Y; Kammori M; Yamada O; Yamazaki K; Ito K; Fukumori T; Yoshikawa K; Yamada T
    Ann Surg Oncol; 2014 Jul; 21(7):2318-25. PubMed ID: 24562933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of mir-129-1, miR-146b, mir-183, and mir-197 in follicular thyroid carcinoma and adenoma tissues.
    Sheikholeslami S; Shabani N; Shivaee S; Tavangar SM; Yeganeh M; Hedayati M; Lotfi J; Gholami H
    Mol Cell Probes; 2020 Jun; 51():101536. PubMed ID: 32081771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spatial Distribution Patterns of Clinically Relevant TERT Promoter Mutations in Follicular Thyroid Tumors of Uncertain Malignant Potential: Advantages of the Digital Droplet PCR Technique.
    Hysek M; Jatta K; Hellgren LS; Stenman A; Larsson C; Zedenius J; Juhlin CC
    J Mol Diagn; 2021 Feb; 23(2):212-222. PubMed ID: 33197629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Ultrasonography Features of Follicular Thyroid Carcinoma With Tumor Invasiveness and Prognosis Based on WHO Classification and TERT Promoter Mutation.
    Kim MK; Park H; Oh YL; Shin JH; Kim TH; Hahn SY
    Korean J Radiol; 2024 Jan; 25(1):103-112. PubMed ID: 38184773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Follicular Thyroid Neoplasms: Comparison of Clinicopathologic and Molecular Features of Atypical Adenomas and Follicular Thyroid Carcinomas.
    Cracolici V; Ritterhouse LL; Segal JP; Puranik R; Wanjari P; Kadri S; Parilla M; Cipriani NA
    Am J Surg Pathol; 2020 Jul; 44(7):881-892. PubMed ID: 32282345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The analysis of genetic and clinicopathologic characteristics in patients with follicular thyroid neoplasm].
    Zhang J; Li Y; Lyu N; Ying JM
    Zhonghua Zhong Liu Za Zhi; 2019 Aug; 41(8):594-598. PubMed ID: 31434450
    [No Abstract]   [Full Text] [Related]  

  • 19. Changes in the clinicopathological characteristics and genetic alterations of follicular thyroid cancer.
    Song YS; Lim JA; Min HS; Kim MJ; Choi HS; Cho SW; Moon JH; Yi KH; Park DJ; Cho BY; Park YJ
    Eur J Endocrinol; 2017 Dec; 177(6):465-473. PubMed ID: 28864536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TERT promoter mutational screening as a tool to predict malignant behaviour in follicular thyroid tumours-three examples from the clinical routine.
    Hysek M; Paulsson JO; Wang N; Jatta K; Lindh C; Fuentes-Martinez N; Shabo I; Zedenius J; Juhlin CC
    Virchows Arch; 2018 Nov; 473(5):639-643. PubMed ID: 29860621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.